



Voyager to Present at Upcoming Investor Conferences

09/01/26

LEXINGTON, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced that the company will participate in the following upcoming investor conferences:

- **Wells Fargo 21st Annual Healthcare Conference:** Fireside chat at 3:45 p.m. ET on Tuesday, September 8, 2026, in Boston, MA.
- **2026 Cantor Global Healthcare Conference:** Fireside chat at 8:35 a.m. ET on Friday, September 11, 2026, in New York, NY.
- **Morgan Stanley 24th Annual Global Healthcare Conference:** Fireside chat at 10:45 a.m. ET on Monday, September 14, 2026, in New York, NY.
- **Baird's 2026 Global Healthcare Conference:** Fireside chat at 7:55 a.m. ET on Tuesday, September 15, 2026, in New York, NY.
- **H.C. Wainwright 28th Annual Global Investment Conference:** Fireside chat at 2:30 p.m. ET on Tuesday, September 15, 2026, in New York, NY.

A webcast of the Wells Fargo fireside chat will be available and may be accessed from the Investors section of Voyager's website at ir.voyagertherapeutics.com. A replay of the webcast will be archived on the company's website for at least 30 days.

About Voyager Therapeutics

Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit <http://www.voyagertherapeutics.com>.

Voyager Therapeutics® is a registered trademark, and TRACER™ and Voyager NeuroShuttle™ are trademarks, of Voyager Therapeutics, Inc.

Contacts

Company and Investors: Trista Morrison, NACD.DC, tmorrison@vygr.com

Media: Lisa Guiterman, voyagerpr@scientpr.com

